Rexulti - Otsuka Pharmaceutical Co., Ltd.

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Alzheimer's Dementia

Manufacturers hope to expand labeling on schizophrenia therapy

Pharmaceutical Business Products

Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation

Home Otsuka US

Rexulti: Package Insert

Otsuka America Pharmaceutical 59148003813 - McKesson Medical-Surgical

FDA's Fast-Track for Rexulti Raises Concerns

Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease